AU2007346587C1 - Methods for the treatment of Senile Dementia of the Alzheimer's Type - Google Patents

Methods for the treatment of Senile Dementia of the Alzheimer's Type Download PDF

Info

Publication number
AU2007346587C1
AU2007346587C1 AU2007346587A AU2007346587A AU2007346587C1 AU 2007346587 C1 AU2007346587 C1 AU 2007346587C1 AU 2007346587 A AU2007346587 A AU 2007346587A AU 2007346587 A AU2007346587 A AU 2007346587A AU 2007346587 C1 AU2007346587 C1 AU 2007346587C1
Authority
AU
Australia
Prior art keywords
alkyl
acyl
sdat
glycerol
plasmanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007346587A
Other languages
English (en)
Other versions
AU2007346587B2 (en
AU2007346587A1 (en
Inventor
Dayan Goodenowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Med-Life Discoveries Lp
Original Assignee
Med Life Discoveries Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med Life Discoveries Lp filed Critical Med Life Discoveries Lp
Publication of AU2007346587A1 publication Critical patent/AU2007346587A1/en
Priority to AU2014201707A priority Critical patent/AU2014201707B2/en
Publication of AU2007346587B2 publication Critical patent/AU2007346587B2/en
Application granted granted Critical
Publication of AU2007346587C1 publication Critical patent/AU2007346587C1/en
Assigned to MED-LIFE DISCOVERIES LP reassignment MED-LIFE DISCOVERIES LP Request for Assignment Assignors: PHENOMENOME DISCOVERIES INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AU2007346587A 2007-02-08 2007-08-27 Methods for the treatment of Senile Dementia of the Alzheimer's Type Active AU2007346587C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014201707A AU2014201707B2 (en) 2007-02-08 2014-03-21 Methods for the treatment of Senile Dementia of the Alzheimer's Type

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88888307P 2007-02-08 2007-02-08
US60/888,883 2007-02-08
PCT/CA2007/001472 WO2008095275A1 (en) 2007-02-08 2007-08-27 Methods for the treatment of senile dementia of the alzheimer's type

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014201707A Division AU2014201707B2 (en) 2007-02-08 2014-03-21 Methods for the treatment of Senile Dementia of the Alzheimer's Type

Publications (3)

Publication Number Publication Date
AU2007346587A1 AU2007346587A1 (en) 2008-08-14
AU2007346587B2 AU2007346587B2 (en) 2014-03-27
AU2007346587C1 true AU2007346587C1 (en) 2015-01-22

Family

ID=39537686

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007346587A Active AU2007346587C1 (en) 2007-02-08 2007-08-27 Methods for the treatment of Senile Dementia of the Alzheimer's Type

Country Status (8)

Country Link
US (5) US9034923B2 (enExample)
EP (2) EP2117527B1 (enExample)
JP (1) JP5470050B2 (enExample)
AU (1) AU2007346587C1 (enExample)
CA (2) CA2620274C (enExample)
IL (1) IL200029A0 (enExample)
SG (1) SG173418A1 (enExample)
WO (1) WO2008095275A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2117527B1 (en) 2007-02-08 2020-06-17 Med-Life Discoveries LP Compounds for use in the treatment of senile dementia of the alzheimer's type
TWI475989B (zh) * 2008-12-22 2015-03-11 Phenomenome Discoveries Inc 縮醛磷脂類化合物，含彼之醫藥組成物以及治療老化疾病的方法
CA2774869C (en) 2009-10-01 2017-10-24 Phenomenome Discoveries Inc. Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CA3112564A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CN114236019B (zh) * 2022-02-24 2022-05-06 宝枫生物科技（北京）有限公司 脑白质病变的生物标志物的应用
CN118512461A (zh) * 2024-06-03 2024-08-20 东莞市第八人民医院（东莞市儿童医院） 一种母乳来源磷脂在防治支气管肺发育不良的应用
CN119876292B (zh) * 2025-03-27 2025-06-03 浙江省白马湖实验室有限公司 一种酰胺类缩醛磷脂化合物的制备方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009371A1 (en) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
FR2736265B1 (fr) 1995-07-07 1997-09-26 Forgeot Marcel Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives
US5731354A (en) 1996-05-06 1998-03-24 Clarion Pharmaceuticals Inc. Treatment for the inhibition of neuro-degenerative disease states
US6177476B1 (en) 1998-08-27 2001-01-23 Clarion Pharmaceuticals Inc. Nutritional supplements for replenishing plasmalogens
CA2298181C (en) 2000-02-02 2006-09-19 Dayan Burke Goodnough Non-targeted complex sample analysis
EP1285092A4 (en) 2000-04-14 2003-07-16 Metabolon Inc METHOD FOR DISCOVERY OF MEDICINES, DISEASE TREATMENT AND DIAGNOSIS USE THE METABOLOMICS
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
WO2002021139A2 (en) 2000-09-08 2002-03-14 Oxford Glycosciences (Uk) Ltd. Automated identification of peptides
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2002338348A1 (en) 2001-04-06 2002-10-21 Biovision Ag Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
EP1389306A2 (de) 2001-05-09 2004-02-18 BioVisioN AG Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
NZ534751A (en) 2002-03-22 2007-05-31 Phenomenome Discoveries Inc Method of visualizing non-targeted metabolomic data generated from fourier transform ion cyclotron resonance mass spectrometers
JP2004026803A (ja) * 2002-03-29 2004-01-29 Nof Corp 神経細胞死予防剤
ES2311751T3 (es) 2002-08-23 2009-02-16 Bayer Healthcare Ag Biomarcadores de polipeptidos para la diagnosis de la enfermedad de alzheimer.
SE0203886D0 (sv) * 2002-12-27 2002-12-27 Ltp Lipid Technologies Provide Glycerolesterprodukt och dess användning
US20040191294A1 (en) * 2003-03-27 2004-09-30 Ramaprasad Talahalli Ravichandra Health composition
EP1637161A4 (en) * 2003-04-22 2007-06-27 Astellas Pharma Inc MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST
EP1694816B1 (en) 2003-11-07 2013-08-28 Ciphergen Biosystems, Inc. Biomarkers for alzheimer's disease
WO2005085838A2 (en) 2004-03-02 2005-09-15 Vanderbilt University Computational analysis of mass spectroscopic lipid data
WO2005116659A2 (en) 2004-05-18 2005-12-08 Neurodx, Llc Compositions and methods relating to alzheimer’s disease
WO2007002285A2 (en) * 2005-06-21 2007-01-04 The Trustees Of The University Of Pennsylvania Methods for treating neurological and psychiatric conditions
JP4176749B2 (ja) 2005-07-29 2008-11-05 学校法人帝京大学 疾病検査法
CA2772688A1 (en) 2005-09-12 2007-03-22 Phenomenome Discoveries Inc. Methods for the diagnosis of colorectal cancer and ovarian cancer health states
EP1932164B1 (en) 2005-09-15 2013-04-24 Phenomenome Discoveries Inc. Method and apparatus for fourier transform ion cyclotron resonance mass spectrometry
KR20080104350A (ko) 2006-02-28 2008-12-02 페노미넘 디스커버리스 인코포레이티드 치매 및 다른 신경 장애의 진단을 위한 방법
JP2009538416A (ja) 2006-05-26 2009-11-05 フェノメノーム ディスカバリーズ インク 多発性硬化症を診断するための生物マーカー、及びその方法
JPWO2008093709A1 (ja) 2007-01-30 2010-05-20 株式会社プロジェクト・エム アミロイド蛋白質の凝集抑制および分解促進によりアミロイドーシスと関連する疾患を予防または治療するための組成物
EP2117527B1 (en) 2007-02-08 2020-06-17 Med-Life Discoveries LP Compounds for use in the treatment of senile dementia of the alzheimer's type
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nagan, Narasimhan et al. "Plasmalogens: biosynthesis and functions" Progress in Lipid Research (2001) Vol.40 pages 199 to 220 *

Also Published As

Publication number Publication date
AU2007346587B2 (en) 2014-03-27
CA2620274A1 (en) 2008-06-20
SG173418A1 (en) 2011-08-29
US10123989B2 (en) 2018-11-13
US20160015673A1 (en) 2016-01-21
US20150306057A1 (en) 2015-10-29
EP2620147B1 (en) 2020-06-03
US9034923B2 (en) 2015-05-19
US9517222B2 (en) 2016-12-13
US20120129934A1 (en) 2012-05-24
CA2695167C (en) 2011-11-01
EP2117527A4 (en) 2012-09-12
EP2117527B1 (en) 2020-06-17
US20170056363A1 (en) 2017-03-02
JP5470050B2 (ja) 2014-04-16
JP2010518029A (ja) 2010-05-27
US20130046016A1 (en) 2013-02-21
EP2117527A1 (en) 2009-11-18
IL200029A0 (en) 2010-04-15
CA2620274C (en) 2011-10-04
US8993623B2 (en) 2015-03-31
EP2620147A2 (en) 2013-07-31
CA2695167A1 (en) 2008-06-20
WO2008095275A1 (en) 2008-08-14
AU2007346587A1 (en) 2008-08-14
EP2620147A3 (en) 2013-10-02

Similar Documents

Publication Publication Date Title
AU2007346587C1 (en) Methods for the treatment of Senile Dementia of the Alzheimer's Type
Mielke et al. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease
Goodenowe et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia
Dorninger et al. Homeostasis of phospholipids—the level of phosphatidylethanolamine tightly adapts to changes in ethanolamine plasmalogens
EP2706992B1 (en) Anxiolytic effect of pterostilbene
Emekli-Alturfan et al. The emerging relationship between vitamin K and neurodegenerative diseases: a review of current evidence
US11963939B2 (en) Use of N-acetylcysteine to treat central nervous system disorders
WO2014144776A1 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
EP2145181B1 (en) Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging
Farias et al. Lipid mediators in cerebral spinal fluid of traumatic brain injured patients
Song et al. Effects of dietary glucocerebrosides from sea cucumber on the brain sphingolipid profiles of mouse models of Alzheimer's disease
Yu et al. Membrane aging as the real culprit of Alzheimer’s disease: modification of a hypothesis
Wood et al. Plasmalogen deficit: a new and testable hypothesis for the etiology of Alzheimer’s disease
Chang et al. Parapyruvate, an impurity in pyruvate supplements, induces senescence in human fibroblastic Hs68 cells via inhibition of the α-ketoglutarate dehydrogenase complex
AU2014201707B2 (en) Methods for the treatment of Senile Dementia of the Alzheimer's Type
HK1182935A (en) Compounds for lowering cholesterol
HK1182935B (en) Compounds for lowering cholesterol
HK1131348A (en) Compounds for use in the treatment of senile dementia of the alzheimer's type
HK1131348B (en) Compounds for use in the treatment of senile dementia of the alzheimer's type
Saitoh et al. Changes in the amounts of myelin lipids and molecular species of plasmalogen PE in the brain of an autopsy case with d-bifunctional protein deficiency
WO2007094026A1 (en) Prophylactic and/or therapeutic treatment of proliferative and conformational diseases
Garcia Heredia Influence of paraoxonase-1 deficiency on metabolic alterations and inflammation
Heredia Influence of paraoxonase-1 deficiency on metabolic alterations and inflammation
Di et al. A platform for the analysis of metabolites in endocannabinoids-related pathways.
HK1134136B (en) Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JUL 2014 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JUL 2014

PC Assignment registered

Owner name: MED-LIFE DISCOVERIES LP

Free format text: FORMER OWNER(S): PHENOMENOME DISCOVERIES INC.